Jan van de Winkel, PhD, president and CEO of Genmab, the longtime innovation engine in antibody drug development, discusses its vision for adding a new business identity: commercial driver.

Under terms of the collaboration, Merck will lead the development, manufacturing, and commercialization of LM-299, an investigational bispecific antibody.

The diversification of site-of-care delivery models is accelerating rapidly, creating new go-to-market implications for drug manufacturers—but also new opportunities to drive more fundamental ...